STOCK TITAN

Fortrea (FTRE) Form 144: Vested 4,886 Shares Planned Sale on NASDAQ

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice for Fortrea Holdings, Inc. (FTRE) reports a proposed sale of 4,886 common shares through Fidelity Brokerage Services on NASDAQ with an aggregate market value of $39,160.31 and approximately 90,800,000 shares outstanding. The filer indicates an approximate sale date of 08/19/2025.

The 4,886 shares were acquired on 08/18/2025 by restricted stock vesting from the issuer and were paid as compensation. The filing also discloses a prior sale by Jill G. Mcconnell of 3,130 common shares on 06/03/2025 for gross proceeds of $13,049.91. Contact and filer identifiers are not provided in the visible content.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: A routine insider sale notice: 4,886 vested shares to be sold via broker; prior small sale reported.

This Form 144 is procedural and documents an insider's planned disposal of recently vested restricted stock (acquired 08/18/2025) with an intended sale via Fidelity on NASDAQ on 08/19/2025. The disclosed aggregate value ($39,160.31) is immaterial relative to typical market caps, and the prior reported sale (3,130 shares for $13,049.91) is consistent with small, personal dispositions. The filing contains limited corporate or financial detail and provides no new operational or earnings information.

TL;DR: Compliance filing noting insider sale of vested compensation shares; no adverse disclosures present.

The notice asserts the seller is unaware of any undisclosed material adverse information and references Rule 144 compliance. The document records acquisition by restricted stock vesting and sale logistics but lacks signer identity and full filer contact data in the visible content. As a governance matter, the filing satisfies disclosure of the transaction terms but offers no material governance changes.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for FTRE report?

The Form 144 reports a proposed sale of 4,886 common shares of Fortrea Holdings (FTRE) via Fidelity on NASDAQ with an aggregate market value of $39,160.31 and an approximate sale date of 08/19/2025.

How were the 4,886 FTRE shares acquired?

The shares were acquired on 08/18/2025 through restricted stock vesting from the issuer and the consideration is listed as compensation.

Does the filing show any prior related sales for the insider?

Yes. The filing discloses a prior sale by Jill G. Mcconnell of 3,130 common shares on 06/03/2025 for gross proceeds of $13,049.91.

Is there any material adverse information disclosed about FTRE in this filing?

No. The person for whose account the securities are to be sold represents by signing the notice that they do not know any undisclosed material adverse information.

What outstanding share count is reported in the Form 144?

The filing shows 90,800,000 shares outstanding for the issuer.
Fortrea Holdings

NASDAQ:FTRE

FTRE Rankings

FTRE Latest News

FTRE Latest SEC Filings

FTRE Stock Data

1.61B
91.87M
0.5%
111.46%
11.57%
Biotechnology
Services-medical Laboratories
Link
United States
DURHAM